Is compulsory licensing bad for public health: some critical comments on drug accessibility in developing countries - HAL Accéder directement au contenu
Article dans une revue Applied Health Economics and Health Policy Année : 2017

Is compulsory licensing bad for public health: some critical comments on drug accessibility in developing countries

Résumé

As one of the flexibilities provided by the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishing minimum standards for the protection of property rights, compulsory license (CL) represents a means towards the protection of public health issues within a context of stringent protection of intellectual property rights (IPRs), most notably in poor-resource settings. However, recent literature asserts that CL constitutes a serious limitation to the full enjoyment of property rights by innovators and may therefore threaten drug accessibility in developing countries. This paper outlines the impact of CL on drug accessibility in developing countries by addressing the three main dimensions of accessibility (availability, affordability and quality) and proceeding to a literature survey of key arguments for and against CL. It concludes that CL inhibits neither the availability of essential drugs nor the affordability of life-saving treatments or the supply of high-quality drugs in developing countries, in particular antiretroviral drugs.
Loading...
Fichier non déposé

Dates et versions

hal-01487031, version 1 (10-03-2017)

Identifiants

Citer

Samira Guennif. Is compulsory licensing bad for public health: some critical comments on drug accessibility in developing countries. Applied Health Economics and Health Policy, 2017, ⟨10.1007/s40258-017-0306-1⟩. ⟨hal-01487031⟩
117 Consultations
0 Téléchargements
Dernière date de mise à jour le 07/04/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus